XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
ASSETS    
Cash and cash equivalents $ 31,478 $ 24,647
Marketable securities 44,052 70,323
Prepaid and other current assets 1,760 1,212
Total current assets 77,290 96,182
Property and equipment, net 299 62
Finite-Lived Intangible Assets, Net 352 0
Other assets 588 764
Total assets 78,529 97,008
Liabilities    
Accounts payable 974 1,934
Accrued liabilities 5,417 2,589
Total current liabilities 6,391 4,523
Other long-term liabilities 367 485
Total liabilities 6,758 5,008
Commitments and Contingencies (Note 13)
Stockholders' Equity    
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.000067 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2022 and December 31, 2021, respectively 0 0
Common stock, $0.001 par value, authorized 33,333,333 shares; issued 7,863,340 and 3,986,719 shares at September 30, 2022 and December 31, 2021, respectively; and outstanding, 7,862,602 and 3,985,981 shares at September 30, 2022 and December 31, 2021, respectively 8 4
Additional paid-in capital 574,066 546,044
Treasury stock, at cost; 738 shares at September 30, 2022 and December 31, 2021 (708) (708)
Accumulated deficit (501,251) (453,016)
Accumulated other comprehensive loss (90) (70)
Total Lisata Therapeutics, Inc. stockholders' equity 72,025 92,254
Non-controlling interests (254) (254)
Total stockholders' equity 71,771 92,000
Total liabilities, non-controlling interests and stockholders' equity $ 78,529 $ 97,008